Every material Form 8-K OCTAVE SPECIALTY GROUP INC has filed with the SEC since April 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Octave Specialty Group reported second-quarter 2026 revenue of $83.0 million, up 51% from $55.0 million a year earlier, led by its Insurance Distribution segment and the ArmadaCare acquisition. Net loss attributable to shareholders was $14.4 million, or $(0.33) per diluted share, compared with a $72.7 million loss a year earlier that included discontinued operations. The company will discuss its results and updated 2026 guidance on a call on August 7, 2026.
Total revenue of $83.0 million for Q2 2026, up 51%; Insurance Distribution revenue rose 77% to $58.4 million with 44.1% organic growth
Net loss attributable to shareholders of $14.4 million, or $(0.33) per diluted share, versus $72.7 million, or $(1.51) per share, in Q2 2025
Adjusted EBITDA to shareholders was $3.7 million versus $(4.6) million a year earlier; Everspan combined ratio improved to 100.6% from 106.7%
Octave Specialty Group reported first-quarter 2026 results, with total revenue from continuing operations rising 66% to $104 million, driven by its Insurance Distribution segment and the October 2025 ArmadaCare acquisition. The net loss attributable to shareholders narrowed to $6.9 million, or $0.13 per diluted share, from $46.4 million, or $1.21 per share, a year earlier, though the Specialty P&C Insurance segment posted a loss tied to a litigation settlement.
Total revenues from continuing operations were $104 million, up 66% from $63 million; organic revenue growth in Insurance Distribution was 42%.
Net loss attributable to shareholders was $6.9 million, or $0.13 per diluted share, compared with $46.4 million, or $1.21 per share, in Q1 2025.
Specialty P&C Insurance segment net loss was $7.7 million, driven primarily by $2.1 million of losses and $5.8 million of LAE from settling a potential litigation matter.
Adjusted EBITDA to shareholders was $20.1 million, compared with a loss of $1.3 million in Q1 2025; the company will discuss results on a May 7, 2026 call.
On April 1, 2026, Octave Specialty Group and its subsidiaries entered a First Amendment to their Credit Agreement with Truist Bank as administrative agent, adding a $40,000,000 term loan. Total outstanding term loans are $139,375,000 as of April 1, 2026, and the company pledged its interest in Everspan Holdings, LLC. Proceeds will fund Cirrata UK's obligation to honor put rights exercised in March 2026 by certain minority shareholders of Octave Specialty Limited.
Additional term loan of $40,000,000 under the First Amendment, dated April 1, 2026
Total outstanding term loans of $139,375,000 as of April 1, 2026
Loan proceeds to fund put rights exercised in March 2026 by minority shareholders of Octave Specialty Limited
Company pledged its ownership interests in Everspan Holdings, LLC as part of the amendment
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every OCTAVE SPECIALTY GROUP INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →